Transarterial viroembolization improves the therapeutic efficacy of immune-excluded liver cancer: Three birds with one stone

被引:5
作者
Cao, Yanyan [1 ,2 ]
Xiong, Fu [1 ,2 ]
Kan, Xuefeng [1 ,2 ]
Guo, Xiaopeng [1 ,2 ]
Ouyang, Tao [1 ,2 ]
Wang, Runyang [3 ]
Yang, Junhan [3 ]
Cai, Linkang [3 ]
Liu, Binlei [3 ]
Liang, Bin [1 ,2 ]
Zheng, Chuansheng [1 ,2 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Radiol, Wuhan 430022, Hubei, Peoples R China
[2] Hubei Prov Key Lab Mol Imaging, Wuhan 430022, Hubei, Peoples R China
[3] Hubei Univ Technol, Wuhan 430068, Hubei, Peoples R China
基金
中国国家自然科学基金;
关键词
Liver cancer; Oncolytic virus; Transarterial viroembolization; Immune response; Immune-excluded; HEPATOCELLULAR-CARCINOMA; TUMOR MICROENVIRONMENT; ADENOVIRUS;
D O I
10.1016/j.phrs.2022.106581
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To investigate the mechanism and efficacy of transarterial viroembolization (TAVE) with an oncolytic virus (OH2) for the treatment of liver cancer in rabbit VX2 tumor models. Materials and methods: Subcutaneous tumor and liver cancer models were established to determine the optimal viral titer and administration modality of OH2. Different liver cancer models were established to evaluate the locoregional tumor response, synergistic and standby effects, survival benefit, and specific antitumor immune memory after TAVE treatment. The immune cell densities in tumor tissues were measured. Results: The optimal viral titer of OH2 was 1 x 10(7) CCID50. TAVE was the most effective modality with greater homogeneous OH2 distribution and therapeutic efficacy compared to other administration routes of transarterial virus infusion (TAVI), commonly adopted intratumor injection (TI), and intravenous injection (IV). Additionally, TAVE treatment significantly improved the locoregional tumor response, standby effect, and survival benefit compared to the TAVI, transarterial embolization (TAE), and control groups. TAVE modified the immune cell densities for immune-excluded liver cancer, partially destroyed vessel metastases, and established antitumor immune memory. The synergistic treatment efficacy of TAVE was superior to the simple addition of two independent monotherapies. Conclusion: TAVE was the optimal and a safe modality for treating immune-excluded liver cancer, and its synergistic effect achieved a remarkable tumor response, standby effect, survival benefit, and antitumor immune memory, which providing an innovative therapeutic modality for clinical practice. Data Availability: Data is available from the corresponding author upon requirement.
引用
收藏
页数:10
相关论文
共 21 条
[1]   Antifibrotic Properties of Transarterial Oncolytic VSV Therapy for Hepatocellular Carcinoma in Rats With Thioacetamide-Induced Liver Fibrosis [J].
Altomonte, Jennifer ;
Marozin, Sabrina ;
De Toni, Enrico N. ;
Rizzani, Antonia ;
Esposito, Irene ;
Steiger, Katja ;
Feuchtinger, Annette ;
Hellerbrand, Claus ;
Schmid, Roland M. ;
Ebert, Oliver .
MOLECULAR THERAPY, 2013, 21 (11) :2032-2042
[2]  
Bommareddy PK, 2018, NAT REV IMMUNOL, V18, P498, DOI 10.1038/s41577-018-0014-6
[3]   Hepatocellular carcinoma [J].
Forner, Alejandro ;
Reig, Maria ;
Bruix, Jordi .
LANCET, 2018, 391 (10127) :1301-1314
[4]   From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma [J].
Fu, Yaojie ;
Liu, Shanshan ;
Zeng, Shan ;
Shen, Hong .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (01)
[5]   Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity [J].
Ilkow, Carolina S. ;
Marguerie, Monique ;
Batenchuk, Cory ;
Mayer, Justin ;
Ben Neriah, Daniela ;
Cousineau, Sophie ;
Falls, Theresa ;
Jennings, Victoria A. ;
Boileau, Meaghan ;
Bellamy, David ;
Bastin, Donald ;
de Souza, Christiano Tanese ;
Alkayyal, Almohanad ;
Zhang, Jiqing ;
Le Boeuf, Fabrice ;
Arulanandam, Rozanne ;
Stubbert, Lawton ;
Sampath, Padma ;
Thorne, Steve H. ;
Paramanthan, Piriya ;
Chatterjee, Avijit ;
Strieter, Robert M. ;
Burdick, Marie ;
Addison, Christina L. ;
Stojdl, David F. ;
Atkins, Harold L. ;
Auer, Rebecca C. ;
Diallo, Jean-Simon ;
Lichty, Brian D. ;
Bell, John C. .
NATURE MEDICINE, 2015, 21 (05) :530-U168
[6]   Reconsidering Dexamethasone for Antiemesis when Combining Chemotherapy and Immunotherapy [J].
Janowitz, Tobias ;
Kleeman, Sam ;
Vonderheide, Robert H. .
ONCOLOGIST, 2021, 26 (04) :269-273
[7]   The In Vivo Therapeutic Efficacy of the Oncolytic Adenovirus Delta24-RGD Is Mediated by Tumor-Specific Immunity [J].
Kleijn, Anne ;
Kloezeman, Jenneke ;
Treffers-Westerlaken, Elike ;
Fulci, Giulia ;
Leenstra, Sieger ;
Dirven, Clemens ;
Debets, Reno ;
Lamfers, Martine .
PLOS ONE, 2014, 9 (05)
[8]   Chemoembolization of liver cancer with doxorubicin-loaded CalliSpheres microspheres: plasma pharmacokinetics, intratumoral drug concentration, and tumor necrosis in a rabbit model [J].
Liang, Bin ;
Zhao, Dan ;
Liu, Yiming ;
Guo, Xiaopeng ;
Zhang, Hongsen ;
Zhang, Lijie ;
Zheng, Chuansheng .
DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2020, 10 (01) :185-191
[9]   Oncolytic viruses: overcoming translational challenges [J].
Martinez-Quintanilla, Jordi ;
Seah, Ivan ;
Chua, Melissa ;
Shah, Khalid .
JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (04) :1407-1418
[10]   How We Do It: Administration Guide for Intralesional Immunotherapy With Talimogene Laherparepvec (T-VEC) for Advanced Melanoma [J].
Queen, Dawn ;
Samie, Faramarz H. ;
Zeitouni, Nathalie C. .
DERMATOLOGIC SURGERY, 2020, 46 (11) :1455-1457